Daratumumab-based immunotherapy vs. lenalidomide, bortezomib and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: a systemic review

Overview of attention for article published in Frontiers in oncology, January 2024

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
High Attention Score compared to outputs of the same age and source (81st percentile)

Mentioned by

twitter: 3 X users

Readers on

mendeley: 4 Mendeley

Summary X

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 18,674 followers.

Daratumumab-based immunotherapy vs. lenalidomide, bortezomib and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: a systemic review https://t.co/pFVe3eV35Q

09 Feb 2024

Reply Repost Favourite

RT @FrontOncology: New research: Daratumumab-based immunotherapy vs. lenalidomide, bortezomib and dexamethasone in transplant-ineligible ne…

27 Jan 2024

Reply Repost Favourite

New research: Daratumumab-based immunotherapy vs. lenalidomide, bortezomib and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: a systemic review: Background Since no randomized controlled trials have directly compared… https://t.c

26 Jan 2024

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.